Novo Nordisk A/S (NONOF)
42.42
-1.25
(-2.87%)
USD |
OTCM |
Sep 15, 16:00
Novo Nordisk Price to Book Value : 5.540 for Sept. 15, 2026
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| September 15, 2026 | 5.540 |
| September 14, 2026 | 5.704 |
| September 11, 2026 | 5.641 |
| September 10, 2026 | 5.766 |
| September 09, 2026 | 5.808 |
| September 08, 2026 | 5.936 |
| September 04, 2026 | 6.048 |
| September 03, 2026 | 6.074 |
| September 02, 2026 | 6.120 |
| September 01, 2026 | 5.924 |
| August 31, 2026 | 5.910 |
| August 28, 2026 | 5.880 |
| August 27, 2026 | 6.029 |
| August 26, 2026 | 6.19 |
| August 25, 2026 | 6.286 |
| August 24, 2026 | 6.139 |
| August 21, 2026 | 6.114 |
| August 20, 2026 | 6.052 |
| August 19, 2026 | 5.930 |
| August 18, 2026 | 5.867 |
| August 17, 2026 | 5.892 |
| August 14, 2026 | 5.896 |
| August 13, 2026 | 5.981 |
| August 12, 2026 | 5.970 |
| August 11, 2026 | 6.127 |
| Date | Value |
|---|---|
| August 10, 2026 | 6.174 |
| August 07, 2026 | 6.149 |
| August 06, 2026 | 5.920 |
| August 05, 2026 | 5.852 |
| August 04, 2026 | 5.812 |
| August 03, 2026 | 5.986 |
| July 31, 2026 | 6.009 |
| July 30, 2026 | 6.505 |
| July 29, 2026 | 6.599 |
| July 28, 2026 | 6.531 |
| July 27, 2026 | 6.417 |
| July 24, 2026 | 6.491 |
| July 23, 2026 | 6.351 |
| July 22, 2026 | 6.333 |
| July 21, 2026 | 6.503 |
| July 20, 2026 | 6.511 |
| July 17, 2026 | 6.628 |
| July 16, 2026 | 6.581 |
| July 15, 2026 | 6.547 |
| July 14, 2026 | 6.433 |
| July 13, 2026 | 6.474 |
| July 10, 2026 | 6.296 |
| July 09, 2026 | 6.359 |
| July 08, 2026 | 6.286 |
| July 07, 2026 | 6.511 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Eli Lilly & Co. | 31.57 |
| ALK-Abello A/S | 6.785 |
| H. Lundbeck A/S | 1.631 |
| Dr. Reddy's Laboratories Ltd. | 2.375 |
| Neumora Therapeutics, Inc. | 3.489 |
Price to Book Value Related Metrics
| PE Ratio | 10.37 |
| PS Ratio | 3.665 |
| PEG Ratio | 0.8227 |
| Price to Free Cash Flow | 25.59 |
| Price | 42.42 |
| Earnings Yield | 9.65% |
| Market Cap | 187.51B |
| PEGY Ratio | 0.6154 |
| Operating PE Ratio | 8.077 |
| Normalized PE Ratio | 9.964 |